Pancreatic Cancer Research

ResearcherCalifornia Institute of TechnologyActive in the last 2 years

André E. Nel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5232-4686; OpenAlex author ID A5075548630; NIH RePORTER profile ID 1886419. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 8)
Trials
0
Grants
2
Labs led
1
Collaborators
11
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 grant · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper, 1 grant · 2025: 3 papers

Papers 15

  1. KRAS mRNA Spleen-Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer. Last author DOI 10.1002/advs.202504886↗
  2. Reprogramming the Tolerogenic Immune Response Against Pancreatic Cancer Metastases by Lipid Nanoparticles Delivering a STING Agonist Plus Mutant KRAS mRNA. Last author DOI 10.1021/acsnano.4c14102↗
  3. Reprogramming Immunosuppressive Niches and the Cancer Immunity Cycle in Pancreatic Cancer with Neoantigen mRNA Plus Immune Adjuvant Nanocarrier Strategies. Co-author DOI 10.1021/acsnano.5c14753↗
  4. Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor. Last author DOI 10.1016/j.nantod.2023.102058↗
  5. Correction to "Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-imm… Last author DOI 10.1021/acsnano.3c06667↗
  6. Use of Stromal Intervention and Exogenous Neoantigen Vaccination to Boost Pancreatic Cancer Chemo-Immunotherapy by Nanocarriers. Last author DOI 10.3390/bioengineering10101205↗
  7. Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy. Last author DOI 10.1021/acsnano.2c06300↗
  8. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Co-author DOI 10.1002/advs.202002147↗
  9. Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo-Immunotherapy. Co-author DOI 10.1002/smll.202005993↗
  10. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. First author DOI 10.1016/j.addr.2018.06.014↗
  11. Major effect of transcytosis on nano drug delivery to pancreatic cancer. Co-author DOI 10.1080/23723556.2017.1335273↗
  12. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. Co-author DOI 10.1172/jci92284↗
  13. Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer. Co-author DOI 10.1021/acsnano.5b07781↗
  14. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. Last author DOI 10.1021/acsnano.5b00510↗
  15. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. Last author DOI 10.1021/nn404083m↗

Grants 2

  1. Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy R01CA247666↗
  2. UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer U01CA198846↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiang Wang · 6 shared papers, 2022–2025 · strength 1.76
  2. Lijia Luo · 6 shared papers, 2022–2025 · strength 1.76
  3. Jeffrey I Zink · 1 shared paper, 2 shared grants, 2013–2024 · strength 1.22
  4. Huan Meng · 8 shared papers, 1 shared grant, 2013–2021 · strength 0.98
  5. Xiangsheng Liu · 6 shared papers, 2015–2021 · strength 0.50
  6. Timothy R. Donahue · 2 shared papers, 1 shared grant, 2016–2019 · strength 0.40
  7. Xiao Xu · 1 shared paper, 2025 · strength 0.33
  8. Saborni Chattopadhyay · 1 shared paper, 2023 · strength 0.26
  9. Ying Chao Ji · 2 shared papers, 2021 · strength 0.22
  10. Zev A. Wainberg · 2 shared papers, 2017–2021 · strength 0.17
  11. Huiyu Liu · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.